Neutrophil preservation solution, and preparation method therefor and use thereof

By using a neutrophil preservation solution with specific components and centrifugation with Percoll solution, the problem of neutrophil isolation and preservation has been solved, achieving the isolation and preservation of high-purity and high-activity neutrophils, supporting scientific research and applications.

WO2026237990A1PCT designated stage Publication Date: 2026-11-19MILECELL BIOLOGICAL SCIENCE & TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096648
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing technologies are insufficient for efficiently isolating and preserving neutrophils, resulting in decreased cell purity and activity, which fails to meet the needs of scientific research and applications.

Method used

A neutrophil preservation solution with specific components, including phosphate buffer containing sodium pyruvate, β-mercaptoethanol, NEAA, glucose, ethylenediaminetetraacetic acid, 4-hydroxyethylpiperazine ethanesulfonic acid, and bovine serum albumin, was used in combination with Percoll centrifugation to achieve efficient separation and preservation of neutrophils.

Benefits of technology

It achieves high purity (>90%) and high viability (>90%) separation of neutrophils, with a preservation time of more than 24 hours and basic preservation of cell function, supporting scientific research and application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026096648_19112026_PF_FP_ABST
    Figure CN2026096648_19112026_PF_FP_ABST
Patent Text Reader

Abstract

A neutrophil preservation solution, and a preparation method therefor and the use thereof. The neutrophil preservation solution comprises a phosphate buffer containing a neutrophil-protective component which comprises at least one of sodium pyruvate, β-mercaptoethanol, NEAA, glucose, ethylenediamine tetraacetic acid, 4-hydroxyethyl piperazine ethanesulfonic acid, or bovine serum albumin. A specific neutrophil preservation solution is designed, in which multiple components work synergistically to maintain the original cell morphology, a high cell viability and cell functions for a long period. Moreover, a method for neutrophil isolation, preservation and quality assessment is further developed, which enables the rapid isolation of highly pure neutrophils, thereby promoting the development and application of neutrophils.
Need to check novelty before this filing date? Find Prior Art

Description

A neutrophil preservation solution, its preparation method and application Technical Field

[0001] This invention belongs to the field of primary cell in vitro isolation and preservation technology, and relates to a neutrophil preservation solution, its preparation method and application. Background Technology

[0002] Neutrophils are polymorphonuclear granulocytes, the most numerous immune cells in the human body, accounting for approximately 50-70% of the total number of leukocytes in adult peripheral blood. Neutrophils are the cell-mediated first line of defense against invading pathogens, playing a crucial role in immune defense and considered the most rapid and effective defensive cells against pathogens. With the deepening of research in related fields in recent years, it has been found that neutrophils are also associated with many other diseases besides pathogenic microbial infections, such as chronic inflammatory diseases, non-alcoholic fatty liver disease (NAFLD), and COPD, as well as various autoimmune diseases (such as type 1 diabetes and rheumatoid arthritis). Furthermore, they are closely related to the occurrence and development of tumors. In the tumor microenvironment (TME), neutrophils have different functions, divided into N1 and N2 neutrophils. N1 has anti-tumor activity, while N2 has pro-tumor function. Therefore, neutrophils can promote or inhibit tumor growth, depending on their polarization state. Reducing the activity of N2 in the TME while enhancing the antitumor activity of N1 has become an important research direction in this field. Overall, the demand for in vitro and in vivo studies of neutrophils is constantly increasing, and obtaining high-purity neutrophils has become an urgent and pressing problem to be solved.

[0003] Neutrophils are terminally differentiated cells with a short lifespan. They exist in peripheral blood circulation for 6-24 hours, and studies show their average lifespan in vivo is 5.4 days, which can reach 7 days under inflammatory conditions. Due to limitations in isolation techniques, the half-life of neutrophils isolated and cultured in vitro is less than 24 hours. Furthermore, neutrophils are highly susceptible to the extracellular environment. Some microorganisms, microbial particles, and adhesion molecules can initiate vascular adhesion programs, promote neutrophil migration across the endothelium, and induce NETosis, the innate death program of neutrophils at sites of infection. These objective factors make it difficult to isolate neutrophils from the blood and conduct further scientific research in their original, inactive state.

[0004] Currently, the mainstream methods for neutrophil isolation can be broadly classified into three categories: one is to obtain neutrophils of a certain purity through density gradient separation; the second is to obtain neutrophils directly through sorting magnetic beads; and the third is a combination of the first two methods, that is, to first obtain neutrophils of general purity through density gradient separation, and then to obtain neutrophils of higher purity through magnetic bead sorting. The first type of method can be further divided into several types depending on the density medium and separation method. One type involves directly separating the neutrophil layer from whole blood using a single density gradient medium. However, this method yields neutrophils with low purity and is contaminated with a large number of red blood cells and lymphocytes. Another type involves pre-treating whole blood with 3% or 6% dextran, allowing it to settle naturally to remove some red blood cells, and then performing density gradient separation of neutrophils. While this method can reduce red blood cell contamination to some extent, it does not fundamentally improve neutrophil purity and is cumbersome and time-consuming. Yet another type uses two density gradient media for separation, but due to insufficient optimization of the separation solution ratio and separation conditions, the purity of the obtained neutrophils is often only around 80% (e.g., the method disclosed in CN112941025A). The second type of method can obtain neutrophils with higher purity, but magnetic bead sorting is costly, and given the high sensitivity of neutrophils to their external environment, magnetic beads have potential unknown effects on neutrophils. While the third type of density gradient centrifugation combined with magnetic bead sorting can also obtain neutrophils with high purity, it is cumbersome, time-consuming, and carries the potential unknown effects of magnetic beads.

[0005] Furthermore, given the susceptibility and short lifespan of neutrophils, their activity often declines significantly from the time they are isolated until they are transported and used in experiments. Currently, there are no reports of in vitro preservation methods that allow neutrophils to maintain high activity and function for more than 24 hours after separation.

[0006] In summary, existing technologies are insufficient to meet the demand for high-quality neutrophils. Therefore, establishing a complete set of neutrophil isolation and preservation techniques is both necessary and urgent. Summary of the Invention

[0007] To address the shortcomings of existing technologies and practical needs, this invention provides a neutrophil preservation solution, its preparation method, and its application. This invention designs a neutrophil preservation solution and further develops methods for neutrophil isolation, preservation, and quality identification, aiming to promote the development and application of neutrophils.

[0008] To achieve this objective, the present invention adopts the following technical solution:

[0009] In a first aspect, the present invention provides a neutrophil preservation solution, the neutrophil preservation solution comprising a phosphate buffer containing a neutrophil-protecting component; the neutrophil-protecting component comprising at least one of sodium pyruvate, β-mercaptoethanol, NEAA (non-essential amino acids), glucose, ethylenediaminetetraacetic acid, 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES), or bovine serum albumin.

[0010] In this invention, a specific neutrophil preservation solution is designed, with multiple components working synergistically to maintain the original cell morphology, high cell viability and cell function for a long time, which is beneficial for the preservation and transportation of neutrophils.

[0011] Preferably, the concentration of sodium pyruvate in the neutrophil preservation solution is 0.1~2mM, for example, it can be 0.2, 0.3, 0.4, 0.5, 0.8, 1, 1.2, 1.4, 1.6, 1.8 or 1.9mM.

[0012] Preferably, the concentration of β-mercaptoethanol in the neutrophil preservation solution is 10-100 mM, for example, it can be 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 mM.

[0013] Preferably, the concentration of NEAAs (non-essential amino acids) in the neutrophil preservation solution is 0.05~0.2 mM, for example, it can be 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18 or 0.19 mM. More preferably, the NEAAs include alanine, arginine, aspartic acid, asparagine, cysteine, glutamine, glutamic acid, glycine, histidine, proline, serine and tyrosine.

[0014] Preferably, the concentration of glucose in the neutrophil preservation solution is 1~10mM, for example, it can be 2, 3, 4, 5, 6, 7, 8 or 9mM.

[0015] Preferably, the concentration of ethylenediaminetetraacetic acid in the neutrophil preservation solution is 0.5~3mM, for example, it can be 0.6, 0.7, 0.8, 0.9, 1, 1.2, 1.4, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8 or 2.9mM.

[0016] Preferably, the concentration of 4-hydroxyethylpiperazine ethanesulfonic acid in the neutrophil preservation solution is 1~5 mM, for example, it can be 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.8, 2, 2.2, 2.4, 2.6, 2.8, 3, 3.5, 4, 4.2, 4.4, 4.6, 4.8 or 4.9 mM, etc.

[0017] Preferably, the mass percentage of bovine serum albumin in the neutrophil preservation solution is 0.2% to 2%, for example, it can be 0.3%, 0.4%, 0.5%, 0.6%, 0.8%, 1%, 1.2%, 1.4%, 1.6%, 1.8%, or 1.9%, etc.

[0018] Preferably, the phosphate buffer comprises DPBS buffer.

[0019] Preferably, the neutrophil preservation solution is a DPBS buffer containing 0.1-2 mM sodium pyruvate, 10-100 μM β-mercaptoethanol, 0.05-0.2 mM NEAA (non-essential amino acids), 1-10 mM glucose, 51 mM ethylenediaminetetraacetic acid, 1-5 mM 4-hydroxyethylpiperazine ethanesulfonic acid, and 0.2-2% bovine serum albumin.

[0020] In a second aspect, the present invention provides a method for preparing the neutrophil preservation solution described in the first aspect, the preparation method comprising:

[0021] The neutrophil protection component and phosphate buffer are mixed to obtain the neutrophil preservation solution.

[0022] Thirdly, the present invention provides the application of the neutrophil preservation solution described in the first aspect in the isolation and preservation of neutrophils.

[0023] Fourthly, the present invention provides a method for isolating and preserving neutrophils, the method comprising:

[0024] The first separation solution, the second separation solution, and whole blood were added sequentially to a centrifuge container, and centrifuged to collect neutrophil cells and mix them with the neutrophil preservation solution described in the first aspect.

[0025] This invention designs a specific method for isolating neutrophils, which can achieve simple and rapid separation to obtain high-purity neutrophils. The purity of the isolated neutrophils is greater than 90% (red blood cell contamination less than 1%, lymphocyte contamination less than 5%), the cell viability is greater than 90%, and the separation time is less than 1 hour. Combined with the neutrophil preservation solution, it can achieve rapid preparation and effective preservation of neutrophils, promoting the development and application of neutrophils.

[0026] Preferably, the first separation solution comprises a Percoll solution with a concentration of 72% to 78%, for example, it may be 73%, 74%, 75%, 76% or 77%, etc.

[0027] Preferably, the second separation solution comprises a Percoll solution with a concentration of 60% to 65%, for example, it may be 61%, 62%, 63% or 64%, etc.

[0028] Preferably, the volume ratio of the first separating liquid, the second separating liquid, and whole blood is 1:1:(1~3).

[0029] Preferably, the whole blood is diluted, and the dilution includes diluting the whole blood 1 to 3 times using a buffer or culture medium.

[0030] Preferably, the layers after centrifugation, from bottom to top, are: red blood cell precipitate, separation solution, neutrophil layer, separation solution, white blood cell layer (PBMC layer), and plasma layer.

[0031] Preferably, the centrifugation process includes a first centrifugation process and a second centrifugation process.

[0032] Preferably, the centrifugation speed of the first centrifugation treatment is 200~300×g, for example, it can be 210×g, 220×g, 230×g, 250×g, 260×g, 270×g, 280×g or 290×g, etc., and the time is 10~20min, for example, it can be 11, 12, 13, 14, 15, 16, 17, 18 or 19min, etc.

[0033] Preferably, the centrifugation speed of the second centrifugation treatment is 400~800×g, for example, it can be 410×g, 420×g, 430×g, 450×g, 500×g, 600×g, 700×g, 720×g, 740×g, 760×g or 790×g, etc., and the time is 15~40min, for example, it can be 16, 17, 18, 20, 22, 25, 30, 32, 35, 36, 37, 38 or 39min, etc.

[0034] Preferably, the collection of neutrophil cells specifically includes: transferring neutrophil cells and mixing them with buffer solution, centrifuging to collect the cell pellet, and obtaining neutrophils.

[0035] Preferably, the method for isolating and preserving neutrophils includes the following steps:

[0036] (1) Add the first separation liquid, the second separation liquid and whole blood to the centrifuge container in sequence. The first separation liquid includes a Percoll solution with a concentration of 72% to 78%, and the second separation liquid includes a Percoll solution with a concentration of 60% to 65%. The volume ratio of the first separation liquid, the second separation liquid and whole blood is 1:1:(1 to 3).

[0037] (2) Centrifuge at 250×g for 15 min, centrifuge at 500×g for 20 min, transfer the neutrophil layer cells and mix with buffer, centrifuge at 250~450×g for 5~10 min to collect the cell pellet, obtain neutrophils, and mix with the neutrophil preservation solution described in the first aspect.

[0038] Fifthly, the present invention provides a method for identifying neutrophil quality, the method comprising the following steps:

[0039] (1) Take the isolated neutrophils, count them and detect their viability;

[0040] (2) Neutrophils were mixed with fluorescently labeled anti-human CD235a antibody, anti-human CD66b antibody, anti-human CD45 antibody and anti-human CD16 antibody;

[0041] (3) Perform flow cytometry analysis on the neutrophils processed in step (2).

[0042] Preferably, the neutrophils in step (1) are prepared by the neutrophil isolation and preservation method described in the fourth aspect.

[0043] Preferably, the fluorescent label of the anti-human CD235a antibody is FITC (anti-human CD235a-FITC), the fluorescent label of the anti-human CD66b antibody is PE (anti-human CD66b-PE), the fluorescent label of the anti-human CD45 antibody is APC (anti-human CD45-APC), and the fluorescent label of the anti-human CD16 antibody is PECY7 (anti-human CD16-PECY7).

[0044] Preferably, the method for counting and detecting cell viability in step (1) includes trypan blue cell counting or AO-PI dye counting, etc.

[0045] Preferably, the flow cytometry analysis includes:

[0046] For the FSC / SSC scatter plot, all cell populations are circled except for cell debris; then, for the FSC-A / FSC-H scatter plot, single cell populations are circled; then, CD235a / SSC, CD45 / SSC, and CD16 / CD66b are analyzed in parallel from the single cell populations to analyze erythrocyte contamination, lymphocyte contamination, and neutrophil purity, respectively.

[0047] This invention systematically defines neutrophil purity by analyzing cell viability and combining specific flow cytometry indicators, enabling rapid and accurate assessment of neutrophil quality and guiding multiple processes such as preparation, preservation, transportation, and application.

[0048] Compared with the prior art, the present invention has at least the following beneficial effects:

[0049] This invention designs a specific neutrophil preservation solution with multiple components working synergistically to maintain the original cell morphology, high cell viability and cell function for a long time, which is conducive to the preservation and transportation of neutrophils. Furthermore, it aims to develop methods for neutrophil isolation, preservation and quality identification, in order to promote the development and application of neutrophils. Attached Figure Description

[0050] Figure 1 is a schematic diagram of centrifugation for separating neutrophils.

[0051] Figure 2 shows the preservation results of different component preservation solutions.

[0052] Figure 3 shows the results of quality assessment of isolated neutrophils.

[0053] Figure 4 is a schematic diagram of the test process simulating 48 hours of transportation / storage.

[0054] Figure 5A shows the changes in the number of neutrophils during simulated 48 h of transport / preservation in the preservation solution.

[0055] Figure 5B shows the cell viability results of neutrophils after simulating 48 h of transport / preservation in the preservation solution.

[0056] Figure 5C shows the purity results of neutrophils after simulating 48 h of transport / preservation in the preservation solution.

[0057] Figure 5D shows the ROS generation results of neutrophils during simulated 48 h of transport / preservation in the preservation solution. Detailed Implementation

[0058] The technical solution of the present invention will be further described below with reference to the accompanying drawings and specific embodiments. However, the following examples are merely simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention is determined by the claims.

[0059] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased from legitimate channels.

[0060] In a specific embodiment of the present invention, Percoll was purchased from Cytiva (Cat. 17089102), sodium pyruvate from Thermo Fisher Scientific (Cat. 11360070), β-mercaptoethanol from Aladdin (Cat. M301574-25 mL), NEAA from Thermo Fisher Scientific (Cat. 11140050), glucose from Inokai (Cat. A29556), ethylenediaminetetraacetic acid (EDTA) from Thermo Fisher Scientific (Cat. AM9260G), 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES) from Thermo Fisher Scientific (Cat. 15630130), bovine serum albumin (BSA) from Beyotime (ST2254-5g), and DPBS from Thermo Fisher Scientific (Cat. 14190144). Example 1

[0061] This embodiment describes the isolation of neutrophils.

[0062] 1) Prepare a 50 mL centrifuge tube. First, wet the tube wall with 5 mL of washing solution. After the centrifuge tube has been left for 2 minutes, remove the residual liquid. This step is to reduce the surface tension so that the subsequent addition of separation solution or dilution of whole blood will reduce the interfacial disturbance.

[0063] 2) Using a pipette, slowly add 10 mL of the first separation solution containing 74% Percoll along the wall of the centrifuge tube; tilt the centrifuge tube at a 45-degree angle, and using a pipette, continue to slowly add 10 mL of the second separation solution containing 64% Percoll on top of the first separation solution. Be careful not to disrupt the interface during this step. After adding the second solution, slowly straighten the centrifuge tube.

[0064] 3) Prepare a new 50 mL centrifuge tube, slowly pour fresh whole blood into the centrifuge tube, and add an equal volume of buffer solution to dilute the blood sample (e.g., add 10 mL of RPMI-1640 if 10 mL of whole blood is used).

[0065] 4) Slowly add the diluted whole blood to the upper layer of the second separation medium, being careful not to disrupt the interface between the two media. The effect is shown in Figure 1. The maximum amount of diluted whole blood added is 30 mL. The ratio of the first separation medium, the second separation medium, and the diluted whole blood should be 1:1:2.

[0066] 5) It can process 16 tubes simultaneously, meaning the maximum processed whole blood volume can reach 240 mL.

[0067] 6) Set the centrifuge speed increase and decrease to 1 and 0 respectively, the rotation speed to 250×g, the temperature to room temperature, and centrifuge for 15 minutes;

[0068] 7) Set the centrifuge speed increase and decrease to 1 and 0 respectively, the rotation speed to 500×g, and the temperature to room temperature. Centrifuge again for 20 minutes.

[0069] 8) After centrifugation, it can be observed that there are a total of six layers (as shown in Figure 1), from bottom to top: red blood cell sediment, separation medium, slightly wider white blood cell layer (neutrophil layer), separation medium, narrower white blood cell layer (PBMC layer) and plasma layer.

[0070] 9) Carefully transfer the plasma (if needed), PBMC layer (if needed), and neutrophil layer in sequence using a pipette into new centrifuge tubes.

[0071] 10) Add PBS to the neutrophil suspension to make up to 50 mL, centrifuge at 300×g for 10 min (2-8℃, both acceleration and deceleration speeds are adjusted to 9), and the cell pellet is the neutrophil. Example 2

[0072] This embodiment describes the isolation of neutrophils.

[0073] 1) Prepare a 50mL centrifuge tube. First, wet the tube wall with 5mL of washing solution. After the centrifuge tube has been left for 2 minutes, remove the residual liquid. This step is to reduce the surface tension so that the subsequent addition of separation solution or dilution of whole blood will reduce the interfacial disturbance.

[0074] 2) Using a pipette, slowly add 10 mL of the first separation solution containing 72% Percoll along the wall of the centrifuge tube; tilt the centrifuge tube at a 45-degree angle, and using a pipette, continue to slowly add 10 mL of the second separation solution containing 60% Percoll on top of the first separation solution. Be careful not to disrupt the interface during this step. After adding the second solution, slowly straighten the centrifuge tube.

[0075] 3) Prepare a new 50mL centrifuge tube, slowly pour fresh whole blood into the centrifuge tube, and add an equal volume of buffer solution to dilute the blood sample (e.g., add 10mL of RPMI-1640 if 10mL of whole blood is used).

[0076] 4) Slowly add the diluted whole blood to the upper layer of the second separation medium, being careful not to disrupt the interface between the two media. The effect is shown in Figure 1. The maximum amount of diluted whole blood added is 30 mL. The ratio of the first separation medium, the second separation medium, and the diluted whole blood should be 1:1:1.

[0077] 5) It can process 16 tubes simultaneously, meaning the maximum processed whole blood volume can reach 240 mL.

[0078] 6) Set the centrifuge speed increase and decrease to 1 and 0 respectively, the rotation speed to 200×g, the temperature to room temperature, and centrifuge for 10 minutes;

[0079] 7) Set the centrifuge speed increase and decrease to 1 and 0 respectively, the rotation speed to 400×g, and the temperature to room temperature. Centrifuge again for 40 minutes.

[0080] 8) After centrifugation, it can be observed that there are a total of six layers (as shown in Figure 1), from bottom to top: red blood cell sediment, separation medium, slightly wider white blood cell layer (neutrophil layer), separation medium, narrower white blood cell layer (PBMC layer) and plasma layer.

[0081] 9) Carefully transfer the plasma (if needed), PBMC layer (if needed), and neutrophil layer in sequence using a pipette into new centrifuge tubes.

[0082] 10) Add PBS to the neutrophil suspension to make up to 50 mL, centrifuge at 300×g for 10 min (2-8℃, both acceleration and deceleration speeds are adjusted to 9), and the cell pellet is the neutrophil. Example 3

[0083] This embodiment describes the isolation of neutrophils.

[0084] 1) Prepare a 50mL centrifuge tube. First, wet the tube wall with 5mL of washing solution. After the centrifuge tube has been left for 2 minutes, remove the residual liquid. This step is to reduce the surface tension so that the subsequent addition of separation solution or dilution of whole blood will reduce the interfacial disturbance.

[0085] 2) Using a pipette, slowly add 10 mL of the first separation solution containing 78% Percoll along the wall of the centrifuge tube; tilt the centrifuge tube at a 45-degree angle, and using a pipette, continue to slowly add 10 mL of the second separation solution containing 65% Percoll on top of the first separation solution. Be careful not to disrupt the interface during this step. After adding the second solution, slowly straighten the centrifuge tube.

[0086] 3) Prepare a new 50mL centrifuge tube, slowly pour fresh whole blood into the centrifuge tube, and add an equal volume of buffer solution to dilute the blood sample (e.g., add 10 mL of RPMI-1640 if 10 mL of whole blood is used).

[0087] 4) Slowly add the diluted whole blood to the upper layer of the second separation medium, being careful not to disrupt the interface between the two media. The effect is shown in Figure 1. The maximum amount of diluted whole blood added is 30 mL. The ratio of the first separation medium, the second separation medium, and the diluted whole blood should be 1:1:3.

[0088] 5) It can process 16 tubes simultaneously, meaning the maximum processed whole blood volume can reach 240mL.

[0089] 6) Set the centrifuge speed increase and decrease to 1 and 0 respectively, the rotation speed to 300×g, the temperature to room temperature, and centrifuge for 10 minutes;

[0090] 7) Set the centrifuge speed increase and decrease to 1 and 0 respectively, the rotation speed to 800×g, and the temperature to room temperature. Centrifuge again for 15 minutes.

[0091] 8) After centrifugation, it can be observed that there are a total of six layers (as shown in Figure 1), from bottom to top: red blood cell sediment, separation medium, slightly wider white blood cell layer (neutrophil layer), separation medium, narrower white blood cell layer (PBMC layer) and plasma layer.

[0092] 9) Carefully transfer the plasma (if needed), PBMC layer (if needed), and neutrophil layer in sequence using a pipette into new centrifuge tubes.

[0093] 10) Add PBS to the neutrophil suspension to make up to 50 mL, centrifuge at 300×g for 10 min (2-8℃, both acceleration and deceleration speeds are adjusted to 9), and the cell pellet is the neutrophil.

[0094] The results (Table 1) show that the purity and viability of neutrophils in Examples 1, 2 and 3 are all good (with Example 3 being slightly lower), and the overall effects are comparable.

[0095] Table 1

[0096] Indicators Example 1 Example 2 Example 3 Granulocytes 94.66% 96.40% 95.71% Lymphocytes 3.62% 3.47% 4.27% Erythrocytes 0.74% 0.13% 0.16% White Blood Cells 99.33% 99.87% 99.81% Neutrophils 94.75% 95.40% 87.91% Cell Viability 92% 97% 92% Example 4

[0097] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0098] The preservation solution is a DPBS buffer containing 1 mM sodium pyruvate, 50 μM β-mercaptoethanol, 0.1 mM NEAA (non-essential amino acids), 5 mM glucose, 1 mM EDTA, 1 mM 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES), and 0.5% bovine serum albumin (BSA).

[0099] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution. The recommended cell density range after mixing is 5 × 10⁻⁶. 6 / mL. Example 5

[0100] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0101] The preservation solution is a DPBS buffer containing 0.1 mM sodium pyruvate, 100 μM β-mercaptoethanol, 0.05 mM NEAA (non-essential amino acids), 1 mM glucose, 3 mM ethylenediaminetetraacetic acid, 1 mM 4-hydroxyethylpiperazine ethanesulfonic acid, and 0.2% bovine serum albumin.

[0102] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL). Example 6

[0103] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0104] The preservation solution is a DPBS buffer containing 2 mM sodium pyruvate, 10 μM β-mercaptoethanol, 0.2 mM NEAA (non-essential amino acids), 10 mM glucose, 0.5 mM ethylenediaminetetraacetic acid, 5 mM 4-hydroxyethylpiperazine ethanesulfonic acid, and 2% bovine serum albumin.

[0105] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL). Example 7

[0106] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0107] The preservation solution is an HBSS solution containing 5 mM HEPES and 0.2% HSA.

[0108] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL). Example 8

[0109] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0110] Compared with Example 4, the only difference is that sodium pyruvate is not added to the preservation solution.

[0111] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL). Example 9

[0112] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0113] Compared with Example 4, the only difference is that β-mercaptoethanol is not added to the preservation solution.

[0114] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL). Example 10

[0115] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0116] Compared with Example 4, the only difference is that NEAA (non-essential amino acid) is not added to the preservation solution.

[0117] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL). Example 11

[0118] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0119] Compared to Example 4, the only difference is that glucose is not added to the preservation solution.

[0120] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL). Example 12

[0121] This embodiment provides a neutrophil preservation solution and preserves the cells isolated in Example 1.

[0122] Compared with Example 4, the only difference is that ethylenediaminetetraacetic acid is not added to the preservation solution.

[0123] The neutrophils isolated and prepared in Example 1 were mixed with the neutrophil preservation solution (cell density range 5 × 10⁻⁶). 6 / mL).

[0124] In Examples 4-12, the cell suspension was stored at 4°C. Neutrophil viability was measured at the start of storage and after 24 hours, as shown in Figure 2. Example 4 effectively maintained neutrophil viability (Results of Examples 5 and 6 were similar), while in Examples 7-12, cell viability decreased significantly, with Examples 8 and 9 showing the largest decreases, indicating the important roles of sodium pyruvate and β-mercaptoethanol in the preservation solution. Furthermore, the examples lacking any component failed to achieve the same neutrophil preservation effect as the complete formulation, suggesting a synergistic effect among the components. These results demonstrate that the neutrophil preservation solution with specific components designed in this invention can effectively maintain cell viability. Example 13

[0125] This embodiment provides a method for identifying neutrophil quality.

[0126] 1) Take the neutrophils isolated according to the method of Example 1 and resuspend them in neutrophil preservation solution (refer to Example 4) to 3×10⁻⁶. 6 / mL; trypan blue cell count and cell viability detection were performed.

[0127] 2) Take 200 μL of the above cell suspension and add anti-human CD235a-FITC, anti-human CD66b-PE, anti-human CD45-APC, and anti-human CD16-PECY7. Simultaneously, prepare single-stain tubes with the corresponding antibodies. Incubate at 4°C for 30 min, then wash once with an appropriate amount of FACS buffer (PBS solution containing 1% FBS). Resuspend the cells in 300 μL of FACS buffer and run the sample through the instrument.

[0128] The flow cytometry data analysis was performed using the following gate logic: For the FSC / SSC scatter plot, all cell populations were circled except for cell debris in the lower left corner; then, single cell populations were circled in the FSC-A / FSC-H scatter plots; finally, CD235a / SSC, CD45 / SSC, and CD16 / CD66b were analyzed in parallel from the single cell populations to identify erythrocyte contamination, lymphocyte contamination, and neutrophil purity, respectively. The identification results are shown in Figure 3 and Table 2.

[0129] Table 2

[0130] The percentages of the markers are as follows: granulocytes 94.66%, lymphocytes 3.62%, erythrocytes 0.74%, white blood cells 99.33%, neutrophils 94.75%, and cell viability 92%.

[0131] As can be seen, the present invention can quickly and efficiently separate and obtain high-purity neutrophils, with the purity of the separated neutrophils greater than 90% (red blood cell contamination less than 1%, lymphocyte contamination less than 5%), cell viability greater than 90%, and separation time less than 1 hour. Example 14

[0132] This embodiment utilizes the cell preservation solution from Example 4 to simulate a transport environment (vehicle transport at 2-8℃). Cell viability, cell density, neutrophil purity (analyzed according to the neutrophil quality identification method in Example 13), and changes in cell function were measured at 0h, 6h, 18h, 24h, and 48h after preservation (flowchart shown in Figure 4, with parallel testing using samples from three donors (donor 1, donor 2, and donor 3)). Neutrophil purity was detected by flow cytometry, and neutrophil function was assessed by detecting the ability of neutrophils to produce reactive oxygen species (ROS) under PMA stimulation. The specific procedure for ROS detection is as follows: the required number of neutrophils was calculated, each sample was divided into an activation group and a non-activation group, and then the cell suspension was aliquoted into EP tubes. After centrifugation and removal of supernatant, cells were resuspended in 1 mL of DHR-123 staining working solution and incubated at 37°C for 20 min. After centrifugation and removal of supernatant, cells were washed once with DPBS solution containing 0.5% HSA. PMA working solution was added to the activated group, and an equal volume of PMA solvent was added to the non-activated group. Cells were resuspended and incubated for 1 h. Cells were washed once with DPBS solution containing 0.5% HSA, and ROS generation was analyzed by flow cytometry after resuspending. The results are shown in Figures 5A-5D. The results indicate that the specific preservation solution designed in this invention has a long-lasting preservation effect on neutrophils. Within 48 h, cell viability did not decrease significantly, and cell density and purity did not change significantly. In addition, ROS generation function decreased slightly, but the decrease was not significant, showing an overall excellent preservation effect.

[0133] In summary, this invention designs a specific neutrophil preservation solution with multiple components working synergistically to maintain the original cell morphology, high cell viability, and cell function for a long time. Furthermore, it develops methods for neutrophil isolation, preservation, and quality identification, enabling the rapid isolation and acquisition of high-purity neutrophils, thus promoting the development and application of neutrophils.

[0134] The applicant declares that the above description is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention fall within the protection and disclosure scope of the present invention.

Claims

1. A neutrophil preservation solution, characterized by, The neutrophil preservation solution includes a phosphate buffer containing neutrophil-protecting components; The neutrophil-protective component includes at least one of sodium pyruvate, β-mercaptoethanol, NEAA, glucose, ethylenediaminetetraacetic acid, 4-hydroxyethylpiperazine ethanesulfonic acid, or bovine serum albumin.

2. The neutrophil preservation solution according to claim 1, characterized in that, The concentration of sodium pyruvate in the neutrophil preservation solution is 0.1~2 mM; Preferably, the concentration of β-mercaptoethanol in the neutrophil preservation solution is 10~100 μM; Preferably, the concentration of NEAA in the neutrophil preservation solution is 0.05~0.2 mM; Preferably, the concentration of glucose in the neutrophil preservation solution is 1-10 mM; Preferably, the concentration of ethylenediaminetetraacetic acid in the neutrophil preservation solution is 0.5~3 mM; Preferably, the concentration of 4-hydroxyethylpiperazine ethanesulfonic acid in the neutrophil preservation solution is 1-5 mM; Preferably, the mass percentage of bovine serum albumin in the neutrophil preservation solution is 0.2% to 2%.

3. The neutrophil preservation solution according to claim 1 or 2, characterized in that, The phosphate buffer includes DPBS buffer; Preferably, the neutrophil preservation solution is a DPBS buffer containing 0.1-2 mM sodium pyruvate, 10-100 μM β-mercaptoethanol, 0.05-0.2 mM NEAA, 1-10 mM glucose, 5 mM ethylenediaminetetraacetic acid, 1-5 mM 4-hydroxyethylpiperazine ethanesulfonic acid and 0.2-2% bovine serum albumin.

4. The method for preparing the neutrophil preservation solution according to any one of claims 1 to 3, characterized by, The preparation method includes: The neutrophil protection component and phosphate buffer are mixed to obtain the neutrophil preservation solution.

5. The use of the neutrophil preservation solution according to any one of claims 1-3 in the isolation and preservation of neutrophils.

6. A method of neutrophil isolation and preservation, characterized in that, The method for isolating and preserving neutrophils includes: The first separation solution, the second separation solution, and whole blood were added sequentially to a centrifuge container, and centrifuged to collect neutrophil cells and mix them with the neutrophil preservation solution according to any one of claims 1-3.

7. The neutrophil isolation and preservation method of claim 6, wherein, The first separation solution comprises a Percoll solution with a concentration of 72% to 78%; Preferably, the second separation solution comprises a Percoll solution with a concentration of 60% to 65%.

8. The neutrophil isolation and preservation method according to claim 6 or 7, characterized in that, The volume ratio of the first separation liquid, the second separation liquid, and whole blood is 1:1:(1~3); Preferably, the whole blood is diluted, and the dilution includes diluting the whole blood 1 to 3 times using a buffer or culture medium; Preferably, the layers after centrifugation, from bottom to top, are red blood cell precipitate, separation solution, neutrophil layer, separation solution, white blood cell layer, and plasma layer; Preferably, the centrifugation process includes a first centrifugation process and a second centrifugation process; Preferably, the centrifugation speed of the first centrifugation treatment is 200~300×g, and the time is 10~20 min; Preferably, the centrifugation speed for the second centrifugation treatment is 400~800×g, and the time is 15~40 min; Preferably, the collection of neutrophil cells specifically includes: transferring neutrophil cells and mixing them with buffer solution, centrifuging to collect the cell pellet, and obtaining neutrophils; Preferably, the method for isolating and preserving neutrophils includes the following steps: (1) Add the first separation liquid, the second separation liquid and whole blood to the centrifuge container in sequence. The first separation liquid includes a Percoll solution with a concentration of 72% to 78%, and the second separation liquid includes a Percoll solution with a concentration of 60% to 65%. The volume ratio of the first separation liquid, the second separation liquid and whole blood is 1:1:(1 to 3). (2) Centrifuge at 200~300×g for 10~20 min, centrifuge at 400~800×g for 15~40 min, transfer the neutrophil layer cells and mix with buffer, centrifuge at 250~450×g for 5~10 min to collect the cell pellet, obtain neutrophils, and mix with the neutrophil preservation solution according to any one of claims 1-3.

9. A method of neutrophil quality identification, characterized by, The identification method includes the following steps: (1) Take the isolated neutrophils, count them and detect their viability; (2) Neutrophils were mixed with fluorescently labeled anti-human CD235a antibody, anti-human CD66b antibody, anti-human CD45 antibody and anti-human CD16 antibody; (3) Perform flow cytometry analysis on the neutrophils processed in step (2).

10. The neutrophil quality identification method according to claim 9, characterized by, The neutrophils in step (1) are prepared by the neutrophil isolation and preservation method according to any one of claims 6-8; Preferably, the fluorescent label of the anti-human CD235a antibody is FITC, the fluorescent label of the anti-human CD66b antibody is PE, the fluorescent label of the anti-human CD45 antibody is APC, and the fluorescent label of the anti-human CD16 antibody is PECY7. Preferably, the flow cytometry analysis includes: For the FSC / SSC scatter plot, all cell populations are circled except for cell debris; then, for the FSC-A / FSC-H scatter plot, single cell populations are circled; then, CD235a / SSC, CD45 / SSC, and CD16 / CD66b are analyzed in parallel from the single cell populations to analyze erythrocyte contamination, lymphocyte contamination, and neutrophil purity, respectively.